

Division of Signal Transduction Therapy

Standard Operating Procedure

Preparation of active NEK3 [1 - 506]

<u>Enzyme description:-</u>	NEK3 [1 - 506]
<u>Clone number:-</u>	DU 41229
<u>Source:-</u>	Recombinant
<u>Expression system:-</u>	Baculovirus expression vector system
<u>Tag:-</u>	N-terminal GST
<u>Purification method:-</u>	GSH Sepharose

Calculated molecular mass:-

Monoisotopic 84, 474.84 daltons
Average Mass 84, 528.83 daltons
[cysteines reduced, methionines have not been oxidised]

Theoretical pI:- 6.33

Purity:- >80 %

Activation protocol:- Constitutively active

Enzyme storage buffer:-

50 mM Tris-HCl pH 7.5, 270 mM sucrose, 150 mM NaCl, 0.1 mM EGTA, 10 mM DTT, 0.02 % Brij-35, 0.2 mM PMSF, 1 mM Benzamidine.

Storage temperature:- -70 °C

Assay Buffer:-

50 mM Tris-HCl pH 7.5, 0.1mM EGTA, 10 mM DTT, 10 mM MgAc

Substrate:-

Myelin Basic Protein Final concentration: 0.33 mg/ml

Division of Signal Transduction Therapy

Clone Data Sheet

NEK3 [1 - 506]

Protein NEK3 [1 - 506]

Clone number DU 41229

Species Human

Accession number NM_002498.2

Tags N-terminal GST

Baculovirus expressed protein

```
MSPILGYWKIKGLVQPTRLLEYLEEKYEEHLYERDEGDKWRNK
KFELGLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKE
RAEISMLEGAVLDIRYGVSR IAYS KDFETLKVDFLSKLP EMLKM
FEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKL
VCFKKRIEAIPOIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSD
LEVL FQGPLGSMDDYMLRMI GEGSFGRALLVQHES SNQMFAMK
EIRLPKSFSNTQNSRKEAVLLAKMKHPNIVAFKESFEAEGHLYI
VMEYCDGGDLMQIKQOKGKLPEDMILNWFTQMCLGVNHIHKK
RVLHRDIKSKNIFLTQNGKVKLGDFGSARLLSNPMAFACTYVGT
PYYVPPEIWENLPYNNKSDIWSLGCILYELCTLKHPFQANSWKN
LILKVCQGCISPLPSHYSYELQFLVKQMFKRNPSHRPSATTLLS
RGIVARLVQKCLPPEIMEYGEEVLEEIKNSKHNTPRKKTNPSR
IRIALGNEASTVQEEEQDRKGSHTDLESINENLVESALRRVNRE
EKGNKSVHLRKASSPNLHRRQWEKNVPNTALTALENASILTSSL
TAEDDRGGSVIKYSKNTTRKQWLKETPDTLLNILKNADLSLAFQ
TYTIYRPGSEGFLKGPLSEETEASDSVDGGHDSVILDPERLEPG
LDEEDTDFEEDDNPDWVSELKKRAGWQGLCDR
```

Native sequence Amino acids M1 – R506 (end residue) of human NEK3.
Residue M232 of the fusion protein is equivalent to M1 of the native enzyme. The GST tag is located at residues 1 - 220.

Protease cleavage PreScission (LEVL**FQGP**) residues 221 - 228

Cloning sites *Bg*III and *Not*I sites of pFastBac Dual.

Division of Signal Transduction Therapy

Nucleotide sequence of insert

agatctATGGATGACTACATGGTCCTGAGAATGATTGGGGAGGGC
TCCTTCGGCAGAGCTCTTTTGGTTCAGCATGAAAGCAGTAATCAG
ATGTTTGCCATGAAAGAAATAAGGCTTCCCAAGTCTTCTCTAAT
ACACAGAATTCTAGGAAGGAGGCTGTTCTTTTAGCCAAAATGAAA
CACCCTAATATTGTTGCCTTCAAAGAATCATTTGAAGCTGAAGGA
CACTTGTATATTGTGATGGAATACTGTGATGGAGGGGATCTAATG
CAAAGATTAAACAGCAGAAAGGAAAGTTATTTCTGAAGACATG
ATACTTAATTGGTTTACCCAAATGTGCCTTGGAGTAAATCACATT
CACAAGAAACGTGTGCTACACAGAGATATCAAGTCCAAGAATATC
TTCCCTCACTCAGAATGGAAAAGTGAAATTGGGAGACTTTGGATCT
GCCCCTCTTCTCTCCAATCCGATGGCATTGCTTGTACCTATGTG
GGAACCTTATTATGTGCCTCCAGAAATTTGGGAAAACCTGCCT
TATAACAATAAAAGTGACATCTGGTCCTTGGGTGTCATCCTGTAT
GAACTCTGTACCCTTAAGCATCCATTTAGGCAAATAGTTGGAAA
AATCTTATCCTCAAAGTATGTCAAGGGTGCATCAGTCCACTGCCG
TCTCATTACTCCTATGAACTTCAGTTCCTAGTCAAGCAGATGTTT
AAAAGGAATCCCTCACATCGCCCCTCGGCTACAACGCTTCTCTCT
CGAGGCATCGTAGCTCGGCTTGTCCAGAAGTGCTTACCCCCGAG
ATCATCATGGAATATGGTGAGGAAGTATTAGAAGAAATAAAAAAT
TCGAAGCATAACACACCAAGAAAAAACAACCCACAGCAGAATC
AGGATAGCTTTGGGAAATGAAGCAAGCACAGTGCAAGAGGAAGAA
CAAGATAGAAAGGGTAGCCATACTGATTTGGAAAGCATTAATGAA
AATTTAGTTGAAAGTGCAATTGAGAAGAGTAAACAGAGAAGAAAAA
GGTAATAAGTCAGTCCATCTGAGGAAAGCCAGTTCACCAAATCTT
CATAGACGACAGTGGGAGAAAAATGTACCCAATACAGCTCTTACA
GCTTTGGAAAATGCATCCATACTCACCTCCAGTTTAACAGCAGAG
GACGATAGAGGTGGTTCTGTAATAAAGTACAGCAAAAATACTACT
CGTAAGCAGTGGCTCAAAGAGACCCCTGACACTTTGTTGAACATC
CTTAAGAATGCTGATCTCAGCTTGGCTTTTCAAACATACACAATA
TATAGACCAGGTTTCAAGGGTTCTTGAAAGGCCCCCTGTCTGAA
GAAACAGAAGCATCGGACAGTGTGATGGAGGTCACGATTCTGTG
ATTTTGGATCCAGAGCGACTTGAGCCTGGGCTAGATGAGGAGGAC
ACGGACTTTGAGGAGGAAGATGACAACCCCGACTGGGTGTCAGAG
CTGAAGAAGCGAGCTGGATGGCAAGGCCTGTGCGACAGATaagcg
gccgc